Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b, Multi-Centre, Parallel Group, Single Blind Study to Evaluate the Safety, Tolerability and Immunogenicity of a Recombinant Plague Vaccine (rF1 and rV Antigens) in Healthy Subjects

NCT00246467 is registered in ClinicalTrials.gov with PharmAthene UK Limited as lead sponsor.

NCT NCT00246467
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00246467 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b, Multi-Centre, Parallel Group, Single Blind Study to Evaluate the Safety, Tolerability and Immunogenicity of a Recombinant Plague Vaccine (rF1 and rV Antigens) in Healthy Subjects
Lead sponsor
PharmAthene UK Limited
Phase
Phase 1
Overall status
Completed
Start date
October 31, 2005
Completion date
April 30, 2007
Enrollment
123 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

plague